Faculty Bibliography

BACKGROUND: Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates are as high as one-third of the population, depending on the country studied, the age range of the subjects, and the diagnostic criteria used. National estimates of prevalence for the US population are lacking. OBJECTIVE: To examine the public health problem posed by eczema, AD, and eczematous conditions in the United States by analyzing disease and symptom prevalence, estimating the number of undiagnosed cases, and assessing comorbidities. METHODS: A self-administered questionnaire was sent to a sample of households (N = 60,000) representative of the US population. A designated member responded with information on symptoms, diagnoses, and impact for affected household members; 42,249 households (70%) responded, representing 116,202 individuals. Empirical eczema was defined by itching/scratching and red/inflamed rash or excessive dryness/scaling. Empirical AD was defined by itching/scratching and red/inflamed rash, excessive dryness/scaling, skinfold location, early onset, symptoms lasting or 14 days, or a physician diagnosis of asthma or of allergic rhinitis or hay fever. RESULTS: Of the population studied, 17.1% reported at least one of four eczematous symptoms; empirically defined eczema was found in 10.7%, and empirically defined AD was found in 6%. Prevalence decreased with increasing income. Approximately two-thirds of individuals with an empirical diagnosis of eczema or AD had moderate to severe symptoms, one-third had sleep disturbances, and one-quarter had chronic unremitting symptoms. Just over one-third (37.1%) of those with symptoms reported a physician diagnosis. Peak onset for empirical AD occurred in the group of subjects aged <or= 5 years. For empirical eczema, peak onset occurred in the group aged 18 to 29 years, and comorbid asthma and hay fever/allergic rhinitis were more prevalent. CONCLUSIONS: A substantial proportion of the US population has symptoms of eczema or eczematous conditions; 31.6 million met the empirical symptom criteria for eczema, and 17.8 million met the empirical criteria for AD. Most cases are not diagnosed by a physician, which indicates that these conditions are undertreated and/or managed with nonprescription remedies

OBJECTIVE:To estimate the comparative prevalence of bipolar symptoms in respondents with epilepsy vs other chronic medical conditions. METHODS:The Mood Disorder Questionnaire (MDQ), a validated screening instrument for bipolar I and II symptoms, in conjunction with questions about current health problems, was sent to a sample of 127,800 people selected to represent the US adult population on selected demographic variables. A total of 85,358 subjects (66.8%) aged 18 or older returned the survey and had usable data. Subjects who identified themselves as having epilepsy were compared to those with migraine, asthma, diabetes mellitus, or a healthy comparison group with regard to relative lifetime prevalence rates of bipolar symptoms and past clinical diagnoses of an affective disorder. RESULTS:Bipolar symptoms, evident in 12.2% of epilepsy patients, were 1.6 to 2.2 times more common in subjects with epilepsy than with migraine, asthma, or diabetes mellitus, and 6.6 times more likely to occur than in the healthy comparison group. A total of 49.7% of patients with epilepsy who screened positive for bipolar symptoms were diagnosed with bipolar disorder by a physician, nearly twice the rate seen in other disorders. However, 26.3% of MDQ positive epilepsy subjects carried a diagnosis of unipolar depression, and 25.8% had neither a uni- nor bipolar depression diagnosis. CONCLUSION/CONCLUSIONS:Bipolar symptoms occurred in 12% of community-based epilepsy patients, and at a rate higher than in other medical disorders. One quarter were unrecognized.

OBJECTIVES/OBJECTIVE:To assess the frequency of depression symptoms, quality of life, and disability in a community-based sample of epilepsy (EPI), asthma, and healthy control (NCH) subjects, and the relationship of depression with EPI-specific aspects of quality of life, social concerns, antiepileptic drug-related side effects, and employment. METHODS:Mail survey with depression (Center for Epidemiology Studies-Depression Scale [CES-D]), quality of life (Short Form [SF]-36), and Sheehan Disability (SDS) scales to 775 EPI, 395 asthma, and 362 NCH subjects. EPI subjects completed Quality of Life in Epilepsy-89 (QOLIE-89), Social Concerns Index, Adverse Events Profile, and employment questions. RESULTS:A total of 36.5% EPI, 27.8% asthma, and 11.8% NCH were positive on CES-D (p < 0.001). EPI had the most prior consultations and treatments for depression but 38.5% of EPI-CES-D+ and 43.7% of asthma-CES-D+ were never previously evaluated for depression. EPI subjects had worse quality of life on SF-36 subscales and greater SDS disability but were similarly disabled as asthma subjects in the presence of depression. Among EPI subjects, CES-D-based depression was significantly associated with being female, being younger, lower income, worse QOLIE-89 scores, more SDS disability, more social concerns, more adverse drug events, less past-month employment, and fewer working days. CONCLUSIONS:Depression is common in community-based epilepsy and asthma patients, and is associated with diverse impairments.

This study assessed the impact of comorbid depression on health care utilization and health care coverage by people with epilepsy in US communities using a postal survey questionnaire. People with untreated depression used significantly more health resources of all types assessed with and without adjustment for seizure type, seizure recency, and days with epilepsy symptoms. The number of visits to medical doctors and psychiatrists differed significantly among people with no (N = 443), mild to moderate (N = 58), and severe (N = 148) symptoms of depression who were not receiving antidepressant treatment (all P < 0.001). People with current symptoms treated with antidepressants had more medical visits than people with no current symptoms ( P=0.016 ). People with current symptoms but not treated for depression had more medical and psychiatric visits than people with no current symptoms (both P = 0.001). These data highlight the impact of comorbid depression on health care utilization by people with epilepsy.

BACKGROUND: Trichodiscomas are rare hamartomas of the dermal portion of the hair disc, a specialized component of the perifollicular mesenchyme. They are usually found as asymptomatic multiple skin-colored papules on the face and extremities and may have an autosomal dominant inheritance pattern. However, a solitary variant has been described. CASE REPORT: A 78-year-old woman presented with a single, non-pigmented, firm papule on the left tip of the nose, measuring 3.5 mm in diameter. RESULTS: The histological examination revealed the previously described features of a trichodiscoma. The immunohistochemical analysis showed strong immunoreactivity for CD34 in the spindle cell component. Spindle cells were negative for S-100, HMB-45, Melan-A, EMA, neurofilament, desmin, and Factor XIIIa by immunohistochemistry. CONCLUSIONS: We report strong reactivity for CD34 in the spindle cell component of a trichodiscoma. We suggest that this lesion be considered in the differential diagnosis of any CD34+ dermal spindle cell proliferation, in which an adjacent epithelial component cannot be entirely excluded

PURPOSE/OBJECTIVE:To determine the relation between depressive symptoms and seizure severity among people with epilepsy. METHODS:A postal questionnaire was used to survey a nationwide community sample about seizures and depression. The Seizure Severity Questionnaire (SSQ) assessed the severity and bothersomeness of seizure components. The Centers for Epidemiological Studies-Depression scale categorized levels of depression. RESULTS:Respondents categorized as having current severe (SEV, n = 166), mild-moderate (MOD, n = 74), or no depression (NO, n = 443) differed significantly in SSQ scores (all p < 0.0001). People with SEV or MOD reported significantly worse problems than did those with NO depression for overall seizure recovery (mean, 5.3, 4.9, 4.5, respectively); overall severity (5.0, 4.5, 4.2); and overall seizure bother (5.3, 4.8, 4.4) (all p < 0.005). Cognitive, emotional, and physical aspects of seizure recovery also were rated worse among people with SEV than with NO depression (all p < 0.05). Symptoms of depression were significantly correlated with higher levels of all components of generalized tonic-clonic seizure severity (r = 0.33-0.48; all p < 0.0001), and partial seizures (r = 0.31-0.38; all p < 0.01). CONCLUSIONS:Clinically depressed people with epilepsy reported higher levels of perceived severity and bother from seizures, as well as greater problems with overall seizure recovery than did nondepressed people experiencing similar types of seizures. The pervasive influence of depressive symptoms on reports of seizure activity suggests that people with epilepsy should be screened for depression. These data highlight the importance of detecting and treating depression among people with epilepsy.

OBJECTIVE: To present the case of an 18-year-old boy with a cleft lip scar and an obligatory need for facial hair who underwent single-follicular-unit graft hair transplantation that resulted in significant moustache hair restoration in a single procedure. SETTING: The surgery was performed in an outpatient private practice setting using oral sedation and local anesthesia. RESULTS: Advances in instrumentation technology and an increased understanding of the anatomical clustering of hair follicles into so-called 'follicular units' containing one to six hairs per unit has resulted in a rapid expansion of hair restoration surgery into new areas including female-pattern alopecia, scarring alopecias, and cosmetic surgery scars. These new techniques can be employed to create natural-looking hair lines in front of artificial hair replacement systems; to improve unnatural looking, old 'large-plug' hair transplants; and to correct discontinuity of eyebrows and hairlines in patients with congenital facial clefts. Increased awareness is needed to incorporate follicular-unit graft hair transplant surgery into the family of corrective surgery subspecialties